Paolo Tralongo, Sebastiano Bordonaro, Giuseppe Di Lorenzo, Ugo De Giorgi, Nicolò Borsellino, Gaetano Facchini, Sabrina Rossetti, Giuseppe Fornarini, Vito Longo, Antonino Carmelo Tralongo, Francesca Caspani, Massimiliano Spada, Nicola Calvani, Paolo Carlini
BACKGROUND: To evaluate the effectiveness and safety of cabazitaxel in castration-resistant prostate cancer patients aged ≥80 years, we performed a retrospective study on a sample of patients from 11 Italian cancer centers. MATERIALS AND METHODS: Fifty-seven patients aged ≥80 years were treated with cabazitaxel after previous failure with docetaxel; 39 completed a comprehensive geriatric assessment questionnaire (34 fit and 5 vulnerable) and 8 patients (14%) had an Eastern Cooperative Oncology Group performance status (PS) ≥2, while most had a PS of 0-1 (86%)...
September 2023: Current Urology